Source: International Congress 2015 – New data on established treatments for asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Zygmunt Podolec (Kraków, Poland), Zygmunt Podolec, Marcin Hartel, Daria Panek, Magdalena Podolec-Rubis, Tomasz Banasik. Effect of inhaled beclomethasone or placebo on brain stem activity in a patient chronically treated with steroids - Preliminary report. Eur Respir J 2015; 46: Suppl. 59, 1021

Member's Comments

No comment yet.

Related content which might interest you: Efficacy and safety of indacaterol acetate on ICS background therapy in asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014 Once-daily tiotropium Respimat add-on to at least ICS in adult patients with symptomatic asthma: Pooled safety analysis Source: International Congress 2014 – Asthma and COPD management Year: 2014 Abediterol: Efficacy, safety and tolerability of the novel LABA in patients with persistent asthma Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 Efficacy and safety of inhaled corticosteroids in combination with a long-acting beta2-agonist in asthmatic children under age 5 Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma Year: 2016 Systemic exposure and lung bioavailability across two different dose strengths of CHF5993 a novel Triple pMDI Source: International Congress 2016 – Pulmonary drug delivery Year: 2016 Prescribed doses and effect on asthma treatment outcomes of extrafine (ciclesonide) vs standard particle inhaled corticosteroids (ICS) Source: International Congress 2015 – Novel targets and strategies for the treatment of cough, asthma, rhinosinusitis and COPD Year: 2015 Pharmacokinetics, safety and tolerability of CHF5993 a triple pMDI in renal impaired patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Pearl's PT010 triple combination provides comparable budesonide exposure to symbicort and comparable glycopyrronium and formoterol exposure to PT003 Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Effect of QVA149 on lung function in the subgroup of patients with a history of exacerbations in the previous year and baseline ICS use from the SHINE study Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Knemometry assessment of short-term lower leg growth in children with asthma treated with fluticasone propionate/formoterol combination therapy Source: International Congress 2015 – Paediatric asthma and allergy: asthma management Year: 2015 Efficacy and safety of VR475 (budesonide suspension delivered by the VR475 Inhalation System) as add-on treatment in patients with severe asthma (CLEARCUT Study) Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 Effect of aclidinium bromide/formoterol fumarate fixed-dose combination (FDC) on night-time and early morning symptoms in COPD Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Individual and differential treatment responses to once-daily long acting bronchodilators, glycopirronium and indacaterol, and combination of both drugs in the patients with moderate or severe COPD Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 24-h efficacy and pharmacokinetics of tiotropium Respimat® 5 μg in patients with asthma Source: International Congress 2015 – Immune mechanisms in the human lung Year: 2015 1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Pharmacokinetics (PK) of indacaterol acetate and mometasone furoate delivered alone or in combination following once daily inhalation in healthy subjects Source: International Congress 2014 – Asthma and COPD management Year: 2014 LATE-BREAKING ABSTRACT: A dose-ranging study of dupilumab in patients (pts) with uncontrolled asthma despite use of inhaled corticosteroids plus a long-acting beta-agonist (ICS/LABA): Final data Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment Year: 2015 Comparative efficacy and costs of the treatment of moderate to severe persistent asthma with a new dry-powder inhaled beclomethasone dipropionate and formoterol combination Source: Annual Congress 2013 –Health economics of airway diseases Year: 2013 Comparative assessment of umeclidinium/vilanterol (UMEC/VI) combination therapy among symptomatic COPD patients Source: International Congress 2014 – Asthma and COPD management Year: 2014 Phase III trial of tiotropium as add-on therapy to low-dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: Design and planned analyses Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013